16th Jul 2014 13:35
LONDON (Alliance News) - GlaxoSmithKline PLC said Wednesday that it has begun shipping its flu vaccine Fluarix Quadrivalent to US healthcare providers after approval from the Food and Drug Administration?s Centre for Biologics Evaluation and Research.
The company said it has also received 2014-15 license approval from its other flu vaccine formulations Fluarix, Flulaval and Flulaval Quadrivalent in the US. It expects to begin shipping Flulaval Quadrivalent and Flulaval in early August. It expects to supply a combined total of around 29 to 33 million doses.
"?Since introducing our own four-strain vaccines last year, we?ve seen a strong uptake. It?s important for consumers to discuss these options with their physicians and get early seasonal protection as the nature and severity of flu seasons can be unpredictable," said Deborah Waterhouse, senior vice president and head of US Vaccines.
Earlier Wednesday Glaxo announced along with Theravance Inc that it has begun a phase II study for its triple combination of fluticasone furoate, umeclidinium and vilanterol for the treatment of chronic obstructive pulmonary disease.
Shares in Glaxo were trading up 0.1% at 1,544.94 pence Wednesday afternoon.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline